AUTHORS
Elnara Fazio-Eynullayeva, MA, Kelley Myers2, Cooper Bussberg3, Jing Voon Chen, PhD4, Emily L. Waters, PhD5, Sanjay Ahuja I, MD, MS6
AFFILIATIONS
1 Novo Nordisk Inc., Plainsboro, New Jersey, United States
2 RTI International, Research Triangle Park, North Carolina, United States
3 RTI International, Research Triangle Park, North Carolina, United States
4 Novo Nordisk Inc., Plainsboro, New Jersey, United States
5 Novo Nordisk Inc., Plainsboro, New Jersey, United States
6 Innovative Hematology Inc., Indianapolis, Indiana, United States
ABSTRACT
Introduction: The hemophilia treatment landscape has evolved substantially with recent approval of new non-factor therapies (NFTs) in the US. While preferences for various attributes of hemophilia factor therapies are well-documented, preferences associated with NFTs are not as clearly characterized. This study quantified patient and caregiver preferences for attributes of NFTs that have been approved in the US or are under development. Preference estimates included the conditional relative importance (CRAI) of NFT attributes, acceptable trade-offs, and predicted treatment choice.
Methods: US adults (aged ≥18 years), adolescents (aged 12-17 years), and caregivers (aged ≥18 years) of children (aged <18 years) with a self-reported physician diagnosis of hemophilia were recruited to participate in a non-interventional, cross-sectional web-based survey conducted between February and August 2025. The survey incorporated a discrete-choice experiment (DCE), a direct elicitation question, and an object-case best-worst scaling (BWS) exercise to assess preferences for NFT attributes and quantify tradeoffs. Attributes were derived from clinical data on US Food and Drug Administration-approved and emerging NFTs, with attribute levels selected to reflect clinically relevant outcome ranges over which respondents would be willing to make trade-offs. Attributes included probability of having a spontaneous bleed, administration mode and frequency, pretreatment requirements, dose determination, storage requirements, and risk of thrombotic events (TEs). Descriptive statistics summarized respondent characteristics and direct elicitation responses. BWS data were analyzed using a random-parameters logit (RPL) model to estimate relative burden weights. DCE data were analyzed using conditional logit and RPL models to estimate attribute preference weights.
Results: The final analysis sample comprised responses from 150 adults, 150 adolescents, and 152 caregivers. Preference weights indicated that respondents preferred treatments with a lower chance of spontaneous bleeds and TE risk. Adult and adolescent respondents preferred autoinjectors and prefilled pens to vials and a syringe, but mode of administration did not have a statistically significant impact on treatment choice among caregivers. CRAI estimates revealed that adults and caregivers placed similar importance on reductions in the likelihood of a spontaneous bleed, in the risk of a TE, and administration frequency. Adolescents considered reductions in administration frequency and likelihood of a spontaneous bleed relatively more important than reducing TE risk. All respondents were willing to accept some level of risk for improvements in efficacy; they required the greatest improvement in the likelihood of a spontaneous bleed to accept a 5% increased risk of a TE and daily administration. In response to the direct elicitation question, when efficacy and risk were held constant, 83.5%-89.8% of respondents preferred a denecimig-like profile over an emicizumab-like profile. When efficacy and risk varied, the probability that an average respondent would choose a denecimig-like profile over an emicizumab-like profile was 81.5%-99.3% for once-monthly and 78.9%-98.8% for once-weekly administration. BWS results indicated that several emicizumab-like treatment features were considered more burdensome relative to denecimig-like features. These included patients needing multiple injections (9.1-16.7 times more burdensome), only 1 week of room temperature storage (4.6-5.6 more burdensome), and a once-monthly or once-weekly treatment with vials and syringe vs a prefilled pen (3-7 times and 1.7-2.6 times more burdensome, respectively).
Conclusion: This is the first study to quantify preferences for differentiating attributes of approved and investigational NFTs while exploring preference heterogeneity in adults, adolescents, and caregivers. Respondents highly valued a denecimig-like profile that is safe and efficacious and mode-related features such as a prefilled pen device and considered a denecimig-like profile to have a lower relative burden compared with an emicizumab-like profile.
DISCLOSURES
Jing Voon Chen, PhD: Novo Nordisk Inc. - Current Employment